文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

整合酶抑制剂耐药:法国HIV-1初治与经治患者全国研究

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该法国多中心研究纳入2014–2017年674例含整合酶链转移抑制剂方案失败患者,90%为经治患者,58%失败时无整合酶耐药相关突变。失败时高病毒载量及低基因型敏感性评分与耐药突变出现相关,多替拉韦失败者耐药突变显著少于拉替拉韦或埃替拉韦。

要点

  • 病毒学失败时58%患者未检出整合酶耐药突变,经治患者占90%。
  • 高病毒载量与低基因型敏感性评分是整合酶耐药突变出现的强相关因素。
  • 多替拉韦失败者整合酶耐药突变显著少于拉替拉韦和埃替拉韦失败者。

核心结论

  • 常规临床实践中多替拉韦在病毒学失败时整合酶耐药选择方面表现稳健。

研究设计与样本

  • 法国多中心研究收集2014–2017年含整合酶抑制剂方案失败患者数据,失败定义为连续两次血浆病毒载量>50拷贝/mL。
  • 共674例患者,其中拉替拉韦359例、埃替拉韦154例、多替拉韦161例,90%为经治患者。
  • 基线及失败时测序逆转录酶、蛋白酶和整合酶编码区,分析ANRS基因型算法收录的整合酶耐药相关突变。

主要发现

  • 389例(58%)患者失败时无整合酶耐药相关突变。
  • 失败时高病毒载量(每增加1 log10拷贝/mL,OR=1.2)和低基因型敏感性评分(GSS≥3 vs GSS=0-0.5,OR=0.08)与至少一种整合酶突变出现最强相关。
  • 多替拉韦失败者整合酶耐药突变显著少于拉替拉韦失败者(OR=0.57,P=0.02)和埃替拉韦失败者(OR=0.45,P=0.005)。
  • 68例一线方案失败患者中,拉替拉韦组11/41(27%)、埃替拉韦组7/18(39%)、多替拉韦组0/9出现整合酶耐药突变。

关键数值与推荐

  • 病毒学失败定义:连续两次血浆病毒载量>50拷贝/mL。
  • 整合酶耐药相关突变依据ANRS基因型算法判定。
  • 基因型敏感性评分分组:GSS≥3与GSS=0-0.5比较,OR=0.08。

临床怎么用

  • 含整合酶抑制剂方案失败时应进行整合酶基因型耐药检测以指导后续方案选择。
  • 高病毒载量和低基因型敏感性评分提示整合酶耐药突变风险较高,需加强监测。
  • 多替拉韦治疗失败时整合酶耐药突变发生率较低,但仍需结合耐药检测结果调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing an INSTI-based regimen in clinical practice. METHODS: Data were collected from patients failing an INSTI-containing regimen in a multicentre French study between 2014 and 2017. Failure was defined as two consecutive plasma viral loads (VL) >50 copies/mL. Reverse transcriptase, protease and integrase coding regions were sequenced at baseline and failure. INSTI resistance-associated mutations (RAMs) included in the Agence Nationale de Recherches sur le SIDA genotypic algorithm were investigated. RESULTS: Among the 674 patients, 359 were failing on raltegravir, 154 on elvitegravir and 161 on dolutegravir therapy. Overall, 90% were experienced patients and 389 (58%) patients showed no INSTI RAMs at failure. The strongest factors associated with emergence of at least one INSTI mutation were high VL at failure (OR = 1.2 per 1 log10 copies/mL increase) and low genotypic sensitivity score (GSS) (OR = 0.08 for GSS ≥3 versus GSS = 0-0.5). Patients failing dolutegravir also had significantly fewer INSTI RAMs at failure than patients failing raltegravir (OR = 0.57, P = 0.02) or elvitegravir (OR = 0.45, P = 0.005). Among the 68 patients failing a first-line regimen, 11/41 (27%) patients on raltegravir, 7/18 (39%) on elvitegravir and 0/9 on dolutegravir had viruses with emergent INSTI RAMs at failure. CONCLUSIONS: These results confirmed the robustness of dolutegravir regarding resistance selection in integrase in the case of virological failure in routine clinical care.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Marcelin AG, Grude M, Charpentier C, et al. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019. PMID: 30789205. doi:10.1093/jac/dkz021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。